Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline ...

TTFields treatment following stereotactic radiosurgery prolonged the time to intracranial progression for patients with brain metastases from NSCLC.

Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.

Among patients with operable, newly diagnosed brain metastases, treatment with GammaTile was associated with a greater than ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...

Exploring the relationship between cancer cells and nerve cells, which can signal tumors to grow, could unearth ways to slow disease.

Clarity Pharmaceuticals Ltd. (($AU:CU6)) announced an update on their ongoing clinical study. Clarity Pharmaceuticals Ltd. is conducting a Phase 3 ...

BERLIN -- Almost half of patients with advanced ALK -positive non-small cell lung cancer (NSCLC) have lived 7 years or longer ...

The survival of patients with metastases is variable ranging from a matter of months to many years. The ability to predict prognosis and response to treatment has a considerable impact on patient ...

Cancer researchers have completed one of the most comprehensive studies of the cells inside melanoma brain metastases. Brain metastasis is one of the most common causes of cancer-related deaths and ...

A study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful ...